DDInter1533 DDInter1676
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Promethazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propiomazine
Promethazine {u} (Compound) resembles {v} (Compound) Chlorprothixene
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promethazine {u} (Compound) binds {v} (Gene) CALM3
Promethazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Promethazine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Promethazine (Compound) resembles Ethopropazine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Promethazine (Compound) resembles Chlorprothixene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine (Compound) binds CALM3 (Gene)
Promethazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Promethazine (Compound) causes Decreased appetite (Side Effect)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Promethazine may lead to a major life threatening interaction when taken with Toremifene